[18F] F-GLN PET/CT Imaging for Breast Cancer
([18F]F-GLN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses a special scan to see how a substance is absorbed by breast cancer cells in adults with significant lesions. The scan helps doctors understand the activity of the cancer by showing how much of the substance the cancer cells take up.
Who Is on the Research Team?
Austin Pantel, MD
Principal Investigator
Instructor of Radiology
Are You a Good Fit for This Trial?
This trial is for adults with breast cancer who have at least one tumor that's 1.5 cm or larger, visible on standard imaging like CT, MRI, mammograms, etc. It's open to those with primary or metastatic breast cancer and requires participants to consent to its investigational nature. Pregnant or breastfeeding women and individuals unable to tolerate imaging procedures are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo dynamic PET scanning and static scans post injection of [18F]F-GLN. Baseline FDG-PET/CT is also performed.
Optional Second Imaging
Some subjects may undergo a second [18F]F-GLN PET/CT and FDG-PET/CT to collect data on changes in uptake in response to therapy.
Follow-up
Participants are monitored for safety and effectiveness after imaging sessions.
What Are the Treatments Tested in This Trial?
Interventions
- Fluoroglutamine [18F]F-GLN
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
University of Pennsylvania
Lead Sponsor